Rivaroxaban for thromboprophylaxis in patients undergoing major orthopedic surgery

Annals of Pharmacotherapy

Volumn 44, Issue 6, 2010, Pages 1061-1071

  Melillo, Stephanie N ^a   Scanlon, James V ^a   Exter, Benjamin P ^a   Steinberg, Michael ^b   Jarvis, Courtney I ^b  

^a BIOGEN   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

BAY 59 7939; Factor Xa inhibitor; Hip replacement; Knee replacement; Rivaroxaban

Indexed keywords

ENOXAPARIN; RIVAROXABAN;

BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG EMBOLISM; MORTALITY; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; REVIEW; THROMBOSIS; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

ANIMALS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MORPHOLINES; ORTHOPEDIC PROCEDURES; POSTOPERATIVE COMPLICATIONS; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 77952994271     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M681     Document Type: Review

References (55)

1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism. Chest 2008;133:381S-453S. DOI 10.1378/chest.08-0656
2. Dahl OE, Caprini JA, Colwell CW, et al. Fatal vascular outcomes following major orthopedic surgery. Thromb Haemost 2005;93:860-866 DOI 10.1160/TH04-11-0769
3. Seagroatt V, Tan HS, Goldacre M. Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. BMJ 1991;303:1431-1435 DOI 10.1136/bmj.303.6815.1431
4. Lieberman JR, Sung R, Dorey F, et al. Low-dose warfarin prophylaxis to prevent symptomatic pulmonary embolism after total knee arthroplasty. J Arthroplasty 1997;12:180-184 DOI 10.1016/S0883-5403(97)90064-4 (Pubitemid 27108289)
5. Lieberman JR, Wollaeger J, Dorey F, et al. The efficacy of prophylaxis with low-dose warfarin for prevention of pulmonary embolism following total hip arthroplasty. J Bone Joint Surg Am 1997;79:319-325 (Pubitemid 27136639)
6. Turpie AG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162:1833-1840 DOI 10.1001/archinte.162.16.1833
7. Howie C, Hughes H, Watts AC. Venous thromboembolism associated with hip and knee replacement over a ten-year period: a population-based study. J Bone Joint Surg Br 2005;87b:1675-1680 DOI 10.1302/0301-620X.87B12.16298 (Pubitemid 43009737)
8. Lotke PA, Lonner JH. The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty. Clin Orthop 2006; 452:175-180 DOI 10.1097/01.blo.0000238822.78895.95 (Pubitemid 44690665)
9. Pellegrini VD, Donaldson CT, Farber DC, et al. The Mark Coventry Award: prevention of readmission for venous thromboembolism after total knee arthroplasty. Clin Orthop 2006;452:21-27 DOI 10.1097/01.blo.0000229357.19867.84
10. NICE. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery. NICE clinical guidelines. www.nice.org.uk/nicemedia/pdf/VTEFullGuide.pdf. (accessed 2009 Nov 2).
11. Scottish Intercollegiate Guidelines Network (SIGN). Prophylaxis of venous thromboembolism. A national clinical guideline. Edinburgh: SIGN Publication, 2002.
12. Package insert. Arixtra (fondaparinux sodium). Research Triangle Park, NC: GlaxoSmithKline, January 2010.
13. Package insert. Coumadin (warfarin sodium). Princeton, NJ: Bristol-Myers Squibb, January 2009.
14. Summary of product characteristics. Xarelto (rivaroxaban) Leverkusen, Germany: Bayer HealthCare, May 2009.
15. Product monograph. Xarelto (rivaroxaban). Toronto, Ontario: Bayer Inc., September 2008.
16. EMEA: Committee for medicinal products for human use. London: European Medicines Agency; c2004-2009. CHMP Assessment Report for Xarelto; 2008. http://www.emea.europa.eu/humandocs/PDFs/EPAR/xarelto/H-944-en6.pdf (accessed 2009 Nov 1).
17. Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) Study. Circulation 2007;116:180-187 DOI 10.1161/CIRCULATIONAHA.106.668020 (Pubitemid 47057524)
18. Buller HR, Lensing AW, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008;112:2242-2247 Epub 2008 Jul 11. DOI 10.1182/blood-2008-05-160143
19. Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009;374:29-38. DOI 10.1016/S0140-6736(09) 60738-8
20. Rivaroxaban. Identifier NCT00494871. Bethesda, MD: US National Institutes of Health. www.clinicaltrials.gov (accessed 2009 Nov 3).
21. Rivaroxaban. Identifier NCT00571649. Bethesda, MD: US National Institutes of Health. www.clinicaltrials.gov (accessed 2009 Nov 3).
22. Rivaroxaban. Identifier NCT00439725. Bethesda, MD: US National Institutes of Health. www.clinicaltrials.gov (accessed 2009 Nov 3).
23. FDA issues complete response letter for rivaroxaban. Johnson & Johnson. http://www.jnj.com/connect/news/all/20090528-103000 (accessed 2010 Feb 11).
24. Update on status of rivaroxaban complete response letter from U.S. FDA. Bayer HealthCare. http://www.viva.vita.bayerhealthcare.com/index. php?id= 36&no-cache=1&tx-ttnews%5Btt-news%5D=13253 (accessed 2010 Feb 12).
25. Chen T, Lam S. Rivaroxaban. Cardiology in review 2009;17:192-197 DOI 10.1097/CRD.0b013e3181aa2154
26. Gulseth MP, Michaud J, Nutescu EA. Rivaroxaban: an oral direct inhibitor of factor Xa. Am J Health Syst Pharm 2008;65:1520-1529 DOI 10.2146/ajhp070624
27. Abrams PJ, Emerson CR. Rivaroxaban: a novel, oral, direct factor Xa inhibitor. Pharmacotherapy 2009;29:167-181 DOI 10.1592/phco.29.2.167
28. FDA: Cardiovascular and Renal Drugs Advisory Committee: Rockville, MD: Food and Drug Administration; c2009. Briefing document for rivaroxaban; 2009 Mar 19. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/CardiovascularandRenalDrugs AdvisoryCommittee/UCM138385.pdf (accessed 2009 Nov 02).
29. Perzborn E. Factor Xa inhibitors-new anticoagulants for secondary haemostasis. Hamostaseologie 2009;29:260-267
30. Roehrig S, Straub A, Pohlmann J, et al Discovery of the novel antithrombotic agent 5-Chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin- 4-yl) phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 2005;48:5900-5908 DOI 10.1021/jm0501 01d
31. Eriksson BI, Borris L, Dahl OE, et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thomb Haemost 2006;4:121-128 DOI 10.1111/j.1538-7836.2005.01657.x
32. Graff J, von Hentig N, Misselwitz F, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 2007;47:1398. DOI 10.1177/ 0091270007302952
33. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Rivaroxaban (BAY 59- 7939) - an oral, direct factor Xa inhibitor - has no clinically relevant interaction with naproxen. Br J Clin Pharmacol 2006;63:469-476 DOI 10.111/j1365-2125.2006. 02776.x (Pubitemid 46426627)
34. Kubitza D, Becka M, Wolfgang M, Zuehlsdorf M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct factor Xa inhibitor - are not affected by aspirin. J Clin Pharmacol 2006;46:981-990 DOIL 10.1177/00912700062921 (Pubitemid 44215062)
35. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358:2765-2775 DOI 10.1056/NEJMoa0800374 (Pubitemid 351930851)
36. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-39 DOI 10.1016/S0140-6736(08)60880-6
37. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358:2776-2786 DOI 10.1056/NEJMoa076016 (Pubitemid 351930852)
38. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomised trial. Lancet 2009;373:1673-1680 DOI 10.1016/S0140-6736(09)60734-0
39. Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005;3:2479-2486 DOI 10.1111/j. 1538-7836.2005.01602.x
40. Eriksson BI, Borris L, Dahl OE, et al. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006;4:121-128 DOI 10.1111/j.1538-7836.2005.01657. x (Pubitemid 44847454)
41. Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006;114:2374-2381 DOI 10.1161/CIRCULATIONAHA.106. 642074
42. Eriksson BI, Borris LC, Dahl OE, et al. Dose-escalation study of rivaroxaban (BAY 59-7939) - an oral, direct factor Xa inhibitor - for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thrombos Res 2007;120:685-693 DOI 10.1016/j.thromres.2006.12.025
43. Melnikova I. The anticoagulants market. Nat Rev Drug Discov 2009; 8:353-354 DOI 10.1038/nrd2851
44. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference of Antithrombotic and Thrombolytic Therapy. Chest 2004;126:338-400S.
45. EMEA: Committee for medicinal products for human use. London: European Medicines Agency; c2004-2009. Guideline on clinical investigation of medicinal products for prophylaxis of high intra- and post-operative venous thromboembolic risk; 2007 Nov 15. http://www.emea.europa.eu/pdfs/human/ewp/70798en-fin.pdf (accessed 2009 Nov 03).
46. Rivaroxaban. Identifier NCT00831714. Bethesda, MD: US National Institutes of Health. www.clinicaltrials.gov (accessed 2009 Nov 03).
47. Comp PC, Spiro TE, Friedman RJ, Whitsett TL, Johnson GJ, Gardiner GA. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. J Bone Joint Surg Am 2001;83: 336-345 DOI 10.1007/s00402-004-0720-3
48. Package insert. Lovenox (enoxaparin sodium). Bridgewater, NJ: sanofiaventis, December 2009.
49. Turpie AG, Bauer KA, Eriksson BI, Lassen MR; PENTATHALON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002;359:1721-1726 DOI 10.1016/S0140-6736(02)08648-8
50. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007;47:218-226 DOI 10.1177/0091270006296058 (Pubitemid 46146488)
51. Bauer KA, Eriksson BI, Lassen MR, Turpie AG; Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-1310 DOI 10.1056/NEJMoa011099
52. Lassen MR, Bauer KA, Eriksson BI, Turpie AG; European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002;359:1715-1720 DOI 10.1016/S0140-6736(02)08652-X (Pubitemid 34607083)
53. RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24:1-9. DOI 10.1016/j.arth.2008.01.132
54. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-956 DOI 10.1016/S0140-6736(07)61445-7 (Pubitemid 47393577)
55. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate versus subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-2185 DOI 10.1111/j.1538-7836.2007.02748.x (Pubitemid 47617868)